<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553135</url>
  </required_header>
  <id_info>
    <org_study_id>20150371</org_study_id>
    <nct_id>NCT02553135</nct_id>
  </id_info>
  <brief_title>Choroideremia Gene Therapy Clinical Trial</brief_title>
  <official_title>An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Byron Lam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The
      study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients
      will be required to attend a total of 11 study visits over a 24 month period with an
      additional 3 year follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open label study involving patients with a clinical phenotype of
      choroideremia and a confirmed CHM genotype. Following consent, patients will be required to
      attend an initial screening visit (Visit 1). Within 2 weeks of the screening visit patients
      will undergo a surgical procedure (Visit 2) under general anesthesia which will include a
      standard vitrectomy, retinal detachment and administration of a subretinal injection of
      AAV2-REP1 (1x1011 genome particles). Patients will be required to attend a further 9 study
      visits (Visits 3-11) over a 24 month period for functional, and anatomical assessments as
      well as monitoring of adverse events. The primary endpoint is the change from baseline in
      visual acuity in the study eye, compared to control eye. Secondary study endpoints are,
      change from baseline in autofluorescence evaluation, microperimetry readings and other
      anatomic and functional outcomes (all in the study eye compared to control eye). Secondary
      endpoints also include safety assessments to be conducted throughout the study. The fellow
      eyes of these patients will be utilized as controls in this study and will receive no study
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best Corrected Visual Acuity From Baseline</measure>
    <time_frame>Baseline, 24 Months</time_frame>
    <description>Patients will have an assessment of visual acuity using the Early Treatment of Diabetic Retinopathy Study (ETDRS) vision charts in both eyes. Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the Patient determines the worse eye be selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Retinal Macular Autofluorescence From Baseline</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Measured in mm^2 by Fundus Autofluorescence and shows changes in the integrity and metabolism of retinal cells. A negative change from baseline indicates a decrease in size of the retained retina (worsening; disease progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Microperimetry From Baseline</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Microperimetry assessments. A negative change from baseline indicates disease worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events during treatment and follow-up period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>Injection of AAV2-REP1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection of AAV2-REP1 (10e11 vg)</intervention_name>
    <description>Single Group: single arm study</description>
    <arm_group_label>Injection of AAV2-REP1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 Years and older

          -  Male

          -  Able to give informed consent

          -  Genetically confirmed diagnosis of choroideremia

          -  Active disease visible clinically within the macula region

          -  Best-corrected visual acuity equal to or worse than 20/32 but better than or equal to
             20/200 in the study eye.

        Exclusion Criteria:

          -  Female

          -  Under the age of 18

          -  History of amblyopia in the study eye

          -  Men unwilling to use barrier contraception methods

          -  Relevant grossly asymmetrical disease or other ocular morbidity which might confound
             use of the fellow eye as a long-term control

          -  Any other significant ocular and non-ocular disease/disorder or retinal surgery

          -  Contraindication to use of medications or contrast agents

          -  Participated in research study involving an investigational product in the past 12
             weeks

          -  Having had gene or cellular therapy at any time prior to this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BYRON LAM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSITY OF MIAMI, BASCOM PALMER EYE INSTITUTE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <results_first_submitted>June 30, 2019</results_first_submitted>
  <results_first_submitted_qc>July 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2019</results_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Byron Lam</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>choroideremia, gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT02553135/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Injection of AAV2-REP1</title>
          <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Injection of AAV2-REP1</title>
          <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Best Corrected Visual Acuity From Baseline</title>
        <description>Patients will have an assessment of visual acuity using the Early Treatment of Diabetic Retinopathy Study (ETDRS) vision charts in both eyes. Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the Patient determines the worse eye be selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.</description>
        <time_frame>Baseline, 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection of AAV2-REP1</title>
            <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Best Corrected Visual Acuity From Baseline</title>
          <description>Patients will have an assessment of visual acuity using the Early Treatment of Diabetic Retinopathy Study (ETDRS) vision charts in both eyes. Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the Patient determines the worse eye be selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.</description>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Retinal Macular Autofluorescence From Baseline</title>
        <description>Measured in mm^2 by Fundus Autofluorescence and shows changes in the integrity and metabolism of retinal cells. A negative change from baseline indicates a decrease in size of the retained retina (worsening; disease progression).</description>
        <time_frame>12 and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection of AAV2-REP1</title>
            <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Retinal Macular Autofluorescence From Baseline</title>
          <description>Measured in mm^2 by Fundus Autofluorescence and shows changes in the integrity and metabolism of retinal cells. A negative change from baseline indicates a decrease in size of the retained retina (worsening; disease progression).</description>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Microperimetry From Baseline</title>
        <description>Microperimetry assessments. A negative change from baseline indicates disease worsening.</description>
        <time_frame>Baseline to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection of AAV2-REP1</title>
            <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Microperimetry From Baseline</title>
          <description>Microperimetry assessments. A negative change from baseline indicates disease worsening.</description>
          <units>Average Threshold dB</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.823" spread="1.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experience an Adverse Event</title>
        <description>Adverse events during treatment and follow-up period</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injection of AAV2-REP1</title>
            <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience an Adverse Event</title>
          <description>Adverse events during treatment and follow-up period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Injection of AAV2-REP1</title>
          <description>Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
Injection of AAV2-REP1 (10e11 vg): Single Group: single arm study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vitreous Cells</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anterior Chamber Cells</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Extrafoveal macular retinal hole in area of nonfunctioning retina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subretinal fluid</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Conjunctiva hemorrhage, edema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Byron Lam , MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-326-6021</phone>
      <email>blam@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

